Bibliographic information

GuidelineClinical management of COVID-19: living guideline, 15 September 2022.
Year of Publication2022
Issuing InstitutionWHO

Recommendation

Maintained

In hospitalized children aged 0–18 who meet a standard case definition for multisystem inflammatory syndrome (MIS-C), we suggest using corticosteroids in addition to supportive care (rather than either IVIG plus supportive care, or supportive care alone)

Recommended in favor

Conditional

Notes and Remarks

Practical Info Practical info There are slightly different case definitions for MIS-C (Annex 5). This guideline is applicable for any standard case definition of MISC. Case definitions will continue to be updated as new data emerge. Based on accessibility to corticosteroids being much wider than accessibility to IVIG, the panel suggested that most patients will receive corticosteroids before they receive IVIG, even in patients where both are prescribed. Route: Systemic corticosteroids can be given orally or intravenously. All studies examined intravenous administration. Dose and duration: In the three studies included in the meta-analysis, intravenous methylprednisilone was used at varying doses; one study did not report a dose. The other two reported ranges between 0.8–2.0 mg/kg/day for 5 days; or higher bolus doses of 10–30 mg/kg/day for 3 days. Both lower and higher dose options can be considered. See Annex 4 for study details. Monitoring: It would be prudent to monitor for known complications associated with corticosteroid use, such as hyperglycemia and behavioural changes. Supportive care: Most emphatically, the GDG emphasized the importance of high-quality supportive care to improve the outcomes of these children, apart from specific therapies. Please see the WHO Pocket Book of Hospital Care for Children for syndromic management guidance of severely ill children, including the importance of recognizing other conditions such leading to shock, sepsis and severe infections; as well as guidance from other organizations on supportive management of Kawasaki disease (161). Uncertainties The GDG emphasized the need for further randomized clinical trials in this population with these agents. The panel acknowledged that results of ongoing randomized trials of therapeutic interventions for MIS-C over the next several months were highly likely to upgrade the certainty of evidence and may lead to changes in recommendations. Enrolment of patients into randomized trials should be prioritized.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

Living guidance for clinical management of COVID-19: living guidance, 23 November 2021.

Year2021
InstitutionWorld Health Organization
Guideline

Clinical management of COVID-19: living guideline, 23 June 2022.

Year2022
InstitutionWHO
Guideline

Clinical management of COVID-19: living guideline, 13 January 2023.

Year2023
InstitutionWHO
Guideline

Clinical management of COVID-19: living guideline, 18 August 2023

Year2023
InstitutionWHO
Guideline

Clinical management of COVID-19: living guideline, June 2025

Year2025
InstitutionWorld Health Organization